Holen Sie sich die Stockscreener-App
23.51
0.99%
0.23
Handel nachbörslich:
23.09
-0.42
-1.79%
Schlusskurs vom Vortag:
$23.28
Offen:
$23.26
24-Stunden-Volumen:
1.14M
Relative Volume:
0.79
Marktkapitalisierung:
$2.89B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
19.92
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
+4.21%
1M Leistung:
+12.17%
6M Leistung:
-4.00%
1J Leistung:
+9.45%
1-Tages-Spanne:
$23.19
$23.58
1-Wochen-Bereich:
$22.23
$23.62
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.51 | 2.86B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Bakersfield.com
Catalyst Pharmaceuticals (Nasdaq: CPRX) at BofA CNS Therapeutics Conference Dec. 8 - Stock Titan
Will Catalyst Pharmaceuticals Inc. (CN2) stock benefit from sector leadership2025 Investor Takeaways & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-11-21 01:33:23 - newser.com
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Published on: 2025-11-20 09:43:10 - newser.com
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 - The Globe and Mail
Published on: 2025-11-20 03:16:30 - newser.com
Why Catalyst Pharmaceuticals Inc. (CN2) stock is trending on social media2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
How Catalyst Pharmaceuticals Inc. (CN2) stock stacks up against competitorsWeekly Market Summary & Fast Momentum Stock Entry Tips - newser.com
Relative strength of Catalyst Pharmaceuticals Inc. in sector analysisWeekly Trade Review & Free Technical Confirmation Trade Alerts - newser.com
What analyst consensus says on Catalyst Pharmaceuticals Inc. stockMarket Movers & Proven Capital Preservation Methods - newser.com
Why analysts maintain buy rating on Catalyst Pharmaceuticals Inc. (CN2) stockTrend Reversal & Stepwise Swing Trade Plans - newser.com
Why Catalyst Pharmaceuticals Inc. stock is considered a top pickEarnings Overview Summary & Weekly Top Stock Performers List - newser.com
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ - The Manila Times
Catalyst Pharmaceuticals (NASDAQ: CPRX) Ranks 304 on 2025 Deloitte Technology Fast 500 - Stock Titan
Published on: 2025-11-19 04:42:53 - newser.com
Is Catalyst Pharmaceuticals Inc. stock attractive for retirement portfoliosInsider Buying & Short-Term Trading Alerts - newser.com
Published on: 2025-11-19 00:40:27 - newser.com
Total assets of Catalyst Pharmaceuticals, Inc. – HAM:CN2 - TradingView
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - The Manila Times
Catalyst Pharmaceuticals (NASDAQ: CPRX) to Join Citi 2025 Global Healthcare Conference - Stock Titan
Will Catalyst Pharmaceuticals Inc. stock split again soon2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):